What are the recommended treatment options for Enterococcus infections, including first‑line regimens for ampicillin‑susceptible, vancomycin‑susceptible, and vancomycin‑resistant strains?

Treatment of Enterococcus Infections

For ampicillin-susceptible enterococcal infections, ampicillin or amoxicillin remains the definitive first-line therapy; for vancomycin-susceptible but ampicillin-resistant strains, vancomycin is appropriate; and for vancomycin-resistant enterococci (VRE), linezolid 600 mg IV/PO every 12 hours is the recommended first-line agent 1.

Ampicillin-Susceptible Enterococcus

Ampicillin is the drug of choice for all ampicillin-susceptible enterococcal infections, regardless of site 2, 3. This includes:

• Uncomplicated urinary tract infections: Ampicillin or amoxicillin 500 mg PO/IV every 8 hours 1
• Bacteremia and endocarditis: Ampicillin IV, often combined with an aminoglycoside (gentamicin or streptomycin) for synergistic bactericidal activity 2, 4
• Intra-abdominal infections: Ampicillin combined with gentamicin and metronidazole 5

Critical pitfall: Using vancomycin for ampicillin-susceptible enterococci significantly increases mortality. A 2022 study demonstrated that vancomycin treatment for ampicillin-susceptible enterococcal bacteremia resulted in 61.5% 30-day mortality versus 26% with beta-lactam therapy (OR 4.07 for mortality with vancomycin) 3. This is because enterococci are only bacteriostatic to vancomycin but bactericidal to ampicillin when combined with aminoglycosides.

For serious infections (endocarditis, meningitis, severe bacteremia), add gentamicin for synergy unless high-level aminoglycoside resistance is documented 2, 4. Approximately 50% of isolates at some centers demonstrate high-level gentamicin resistance; in these cases, test for streptomycin susceptibility as an alternative 4.

Vancomycin-Susceptible, Ampicillin-Resistant Enterococcus

This pattern is most commonly seen with Enterococcus faecium. Vancomycin is the appropriate choice for these infections 6, 7. However, recognize that vancomycin provides only bacteriostatic activity against enterococci, which may contribute to treatment failures in severe infections.

For E. faecium bacteremia that is ampicillin-resistant but vancomycin-susceptible, mortality remains high (often >30%) regardless of appropriate therapy, likely reflecting underlying patient severity and comorbidities 7.

Vancomycin-Resistant Enterococcus (VRE)

First-Line Therapy by Infection Site:

Bacteremia and serious systemic infections:

• Linezolid 600 mg IV or PO every 12 hours (strong recommendation) 1
• Alternative: High-dose daptomycin 8-12 mg/kg/day IV, particularly when combined with beta-lactams (ampicillin, cephalosporins, or carbapenems) for potential synergy 1

Intra-abdominal infections:

• Tigecycline 100 mg IV loading dose, then 50 mg IV every 12 hours 1
• Duration based on clinical response and source control

Uncomplicated urinary tract infections (cystitis):

• Single-dose fosfomycin 3 g PO 1
• Nitrofurantoin 100 mg PO every 6 hours 1
• High-dose ampicillin (18-30 g IV daily in divided doses) or amoxicillin 500 mg PO/IV every 8 hours for ampicillin-susceptible VRE strains 1

Important Nuances for VRE Treatment:

Linezolid versus daptomycin: No head-to-head randomized trials exist. Meta-analyses show comparable mortality rates (approximately 33-35%) 1. Linezolid has the advantage of oral bioequivalence and activity against both E. faecium and E. faecalis. Key limitation: Thrombocytopenia with courses >14-21 days. Daptomycin requires higher doses (8-12 mg/kg) than for other Gram-positive infections and shows enhanced activity when combined with beta-lactams 1.

Species-specific considerations:

• VRE E. faecium isolates show >90% susceptibility only to linezolid, with <15% susceptibility to ampicillin, ciprofloxacin, nitrofurantoin, and tetracycline 8
• VRE E. faecalis isolates retain >90% susceptibility to ampicillin, linezolid, and nitrofurantoin 8
• E. gallinarum and E. casseliflavus have intrinsic low-level vancomycin resistance but remain >90% susceptible to ampicillin and nitrofurantoin 8

Critical decision point: Always obtain susceptibility testing. For VRE with high-level resistance to both gentamicin and streptomycin, monotherapy with ampicillin (if susceptible), linezolid, or high-dose daptomycin is appropriate, as no combination provides predictable bactericidal activity 4.

Treatment Duration:

• Bacteremia without endocarditis: 7-14 days after clearance of bacteremia
• Endocarditis: 4-6 weeks minimum
• Intra-abdominal infections: Based on source control and clinical response, typically 4-7 days after adequate drainage
• Uncomplicated UTI: 3-7 days
• Complicated UTI/pyelonephritis: 10-14 days

Avoid unnecessary treatment: Enterococci commonly colonize the urinary tract and gastrointestinal system. Treat only when clinical infection is documented (fever, leukocytosis, symptoms) rather than asymptomatic bacteriuria, particularly in catheterized patients 9.